QUIMILZA
LIVE

Serial Number

99714774

Owner

Vanda Pharmaceuticals Inc.

Attorney

Jayme M Torelli

Filing Date

Mar 20, 2026

Add to watchlist:

No watchlists yet
View on USPTO

QUIMILZA Trademark

Serial Number: 99714774

QUIMILZA is a trademark filed by Vanda Pharmaceuticals Inc. on March 20, 2026. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Vanda Pharmaceuticals Inc. (104 trademarks)

Suite 300
Rockville, MD 20850

Entity Type: 03

Trademark Details

Filing Date

March 20, 2026

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the treatment of generalized pustular psoriasis (GPP); Pharmaceutical preparations for IL-36R inhibition or neutralization; Pharmaceutical preparations for the treatment of a disease or disorder that is responsive to IL-36R inhibition or neutralization, namely, inflammatory diseases, autoimmune diseases, respiratory diseases, metabolic disorders, and cancer; Pharmaceutical preparations for the treatment of an inflammatory disorder, namely, allergic inflammation of the skin, lungs, and gastrointestinal tract, atopic dermatitis or atopic eczema, allergic asthma and non-allergic asthma, epithelial-mediated inflammation, fibrosis, idiopathic pulmonary fibrosis, scleroderma, kidney fibrosis, scarring, allergic rhinitis, food allergies, seasonal allergies, and other allergies; Pharmaceutical preparations for the treatment of an autoimmune disease, namely, multiple sclerosis, asthma, Type 1 diabetes mellitus, rheumatoid arthritis, scleroderma, Crohn's disease, psoriasis vulgaris or psoriasis, pustular psoriasis, generalized pustular psoriasis (GPP), palmo-plantar pustulosis (PPP), inflammatory bowel disease, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, and ankylosing spondylitis; Pharmaceutical preparations for the treatment of a respiratory disease, namely, asthma, cystic fibrosis, emphysema, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome; Pharmaceutical preparations for the treatment of a metabolic disorder, namely, obesity, Type 2 diabetes, atherosclerosis, and cardiovascular disease; Pharmaceutical preparations for the treatment of cancer, namely, melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gall bladder cancer, laryngeal cancer, liver cancer, thyroid cancer, stomach cancer, salivary gland cancer, prostate cancer, pancreatic cancer, leukemia, lymphoma, and Merkel cell carcinoma; Pharmaceutical preparations for the treatment of a chronic skin condition, namely, hidradenitis suppurativa; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 26, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 12, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 12, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 12, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 27, 2026 GNRN
NON-FINAL ACTION E-MAILED
Apr 27, 2026 GNRT
NON-FINAL ACTION WRITTEN
Apr 27, 2026 CNRT
ASSIGNED TO EXAMINER
Apr 17, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 20, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 20, 2026 NWOS
NEW APPLICATION ENTERED
Mar 20, 2026 NWAP